Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Mycobacterium chelonae is a rare cause of chronic disseminated cutaneous infections in immunocompromised patients. Multidrug-resistant M. chelonae infections present a challenge for treatment, and prolonged antimicrobial courses lead to significant toxicities and further antimicrobial resistance. We report a case of refractory cutaneous disseminated M. chelonae infection in a patient with seronegative arthritis on immunotherapy with tofacitinib that was treated with combination antimicrobial, surgical, and single bacteriophage therapy with excellent clinical response. The patient developed neutralizing antibodies against the bacteriophage but continues to have stable improvement of disease with negative biopsies and no evidence of bacterial resistance to the phage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“successfully used to treat chronic, drug-resistant infections of M. abscessus (177–179)”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [177]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Phages have also been explored as diagnostic tools, and successfully used to treat chronic, drug-resistant infections of M. abscessus (177–179).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [177]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacteriophage resistance mechanisms
Labrie, S. J., Samson, J. E., & Moineau, S. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2315 · Cited by 2,397
Dedrick, R. M., Guerrero-Bustamante, C. A., Garlena, R. A., Russell, D. A., Ford, K., Harris, K., Gilmour, K. C., Soothill, J., Jacobs-Sera, D., Schooley, R. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0437-z · Cited by 1,410
Self-citationSchooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Self-citationPhage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 1,180
Spectrum of Disease Due to Rapidly Growing Mycobacteria
Wallace, R. J., Swenson, J. M., Silcox, V. A., Good, R. C., Tschen, J. A., & Stone, M. S. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.4.657 · Cited by 584
Phage Therapy for Antibiotic-Resistant Bacterial Infections
Hatfull, G. F., Dedrick, R. M., & Schooley, R. T. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-080219-122208 · Cited by 571
Self-citationWallace, R. J., Brown, B. A., & Onyi, G. O. (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/166.2.405 · Cited by 361
Wallace, R. J., Meier, A., Brown, B. A., Zhang, Y., Sander, P., Onyi, G. O., & Böttger, E. C. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.7.1676 · Cited by 283
Safranek, T. J., Jarvis, W. R., Carson, L. A., Cusick, L. B., Bland, L. A., Swenson, J. M., & Silcox, V. A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170403 · Cited by 270
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Cited by
Dedrick, R. M., Smith, B. E., Cristinziano, M., Freeman, K. G., Jacobs-Sera, D., Belessis, Y., Whitney Brown, A., Cohen, K. A., Davidson, R. M., van Duin, D., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac453 · Cited by 344
Self-citationNovel antimicrobial agents for combating antibiotic-resistant bacteria
Chang, R. Y. K., Nang, S. C., Chan, H.-K., & Li, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114378 · Cited by 227
The Mechanism of Bacterial Resistance and Potential Bacteriostatic Strategies
Zhang, F., & Cheng, W. (2022) · Antibiotics · doi:10.3390/antibiotics11091215 · Cited by 213
Current Clinical Landscape and Global Potential of Bacteriophage Therapy
Hitchcock, N. M., Devequi Gomes Nunes, D., Shiach, J., Valeria Saraiva Hodel, K., Dantas Viana Barbosa, J., Alencar Pereira Rodrigues, L., Coler, B. S., Botelho Pereira Soares, M., & Badaró, R. (2023) · Viruses · doi:10.3390/v15041020 · Cited by 187
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation
Nang, S. C., Lin, Y.-W., Petrovic Fabijan, A., Chang, R. Y. K., Rao, G. G., Iredell, J., Chan, H.-K., & Li, J. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.01.021 · Cited by 161
Metadata
- Authors
- Little, J. S., Dedrick, R. M., Freeman, K. G., Cristinziano, M., Smith, B. E., Benson, C. A., Jhaveri, T. A., Baden, L. R., Solomon, D. A., & Hatfull, G. F.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pittsburgh (US)
- University of California San Diego (US)
- Corresponding author
- Little, Jessica S.
- ORCID
- Venue
- Nature Communications
- Published
- 2022-05-03
- Volume
- 13
- Issue
- 1
- Pages
- 2313-2313
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9064978
- OpenAlex
- W4225312054
- Cited by
- 128
- References
- 23
- Citations by year
- 2026: 19 · 2025: 32 · 2024: 27 · 2023: 32 · 2022: 18
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | National Institutes of Health (GM131729)
- Howard Hughes Medical Institute (GT12053)
- Cystic Fibrosis Foundation (HATFUL19GO)
- Topics
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- Mycobacterium chelonae, phage therapy, multidrug-resistant mycobacteria, refractory infection, tofacitinib, immunotherapy, seronegative arthritis, immunocompromised patients, neutralizing antibodies, surgical debridement, combination antimicrobial therapy
- MeSH terms
- Anti-Bacterial Agents, Bacteriophages, Humans, Mycobacterium Infections, Nontuberculous, Mycobacterium chelonae, Skin Diseases, Bacterial, Clarithromycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. https://app.cochat.ai/papers/10.1038/s41467-022-29689-4
- The paper
- Little, J. S., Dedrick, R. M., Freeman, K. G., Cristinziano, M., Smith, B. E., Benson, C. A., Jhaveri, T. A., Baden, L. R., Solomon, D. A., & Hatfull, G. F. (2022). Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nature Communications. https://doi.org/10.1038/s41467-022-29689-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.